Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomaglumetad Methionil in PTSD
NCT02234687Phase 1Terminated
- Sponsor
- NYU Langone Health
- Start
- Sep 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of pomaglumetad methionil in post-traumatic stress disorder (PTSD) (3 arms), sponsored by NYU Langone Health. Primary endpoint: Effect of 160mg and 40mg of Pomaglumetad Methionil on Fear-Potentiated Startle Response. Started Sep 2014; status: terminated.
02
Drugs
pomaglumetad methionil
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT02234687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234687.